Leidos Biomedical Research, Inc. (LBRI), a wholly owned subsidiary of Leidos, operates the Frederick National Laboratory for Cancer Research (FNLCR). FNLCR is a Federally Funded Research and Development Center (FFRDC) sponsored by the National Cancer Institute (NCI). It is the only FFRDC dedicated to biomedical research. Through its status as an FFRDC, FNLCR provides NCI and others with a unique national resource to accelerate the development and delivery of effective preventive, diagnostic, and therapeutic products for cancer and AIDS.
The breadth of FNLCR’s activities spans the research and development spectrum, including investigator-initiated, hypothesis-driven research into cancer and AIDS; advanced technology programs focused on genetics and genomics, proteins and proteomics, imaging, nanotechnology, bioinformatics, and laboratory animal sciences; clinical operations in support of NCI and National Institute of Allergy and Infectious Diseases (NIAID)-sponsored clinical trials, as well as NCI drug discovery and development efforts; and management and operations of biopharmaceutical development and manufacturing programs under current Good Manufacturing Practice conditions for NCI and NIAID. Administrative, procurement, financial, safety, and facilities support is provided to these R&D activities through state-of-the-art business processes. LBRI has approximately 1,900 employees and manages an annual operating budget of approximately $450M.
The Basic Science Program (BSP) pursues independent, multidisciplinary research programs in basic or applied molecular biology, immunology, retrovirology, cancer biology or human genetics. Research efforts and support are an integral part of the Center for Cancer Research (CCR). The Microbiome Core undertakes the characterization of microbiome samples by next generation sequencing to determine composition and variation as influenced by immune, genetic, and host health factors. The Microbiome Core provides support across a spectrum of processes, from nucleic acid isolation to bioinformatics and statistical analysis.
The Bioinformatics Analyst III will be responsible for computational handling and analysis of next generation sequences in multiple output file formats for multiple purposes to characterize microbiome samples. This position is located on the NIH Bethesda, MD campus.
Possession of a Bachelor's degree (Mater's preferred) in biomedical science/bioinformatics/math/computer or related field from a college or university or four (4) years related experience in lieu of degree
Foreign degrees must be evaluated for U.S. equivalency
In addition to educational requirements, a minimum of five (5) years related experience in a laboratory environment with a strong background in database management and utility programming
Experience with sequence data formats and processing from next generation platforms (Illumina, 454, etc)
Ability to use common bioinformatic programs and databases in the area of automated bioinformatics workflows (e.g. GALAXY)
Ability to use, maintain, or modify microbiome analysis pipelines (e.g. Qiime, Mothur), and databases (Greengenes)
Ability to set-up and manage databases for storage of sequence and biosample information (SQL, MYSQL, or other database languages)
Ability to program/script in two of the following: C, C++, Perl, Python, and Shell
Strong working knowledge of bioinformatics tools for sequence identification, evaluation and assembly (BLAST, BOWTIE, BWA, etc.)
Experience in statistical data analysis, evaluation and visualization, including strong working knowledge of statistical software (e.g., R, S, SPSS) and heatplots, cladograms, and other methods of data representation
Strong working knowledge of phylogenetic reconstruction methods and programs
Familiarity with laboratory experimental procedures used in data generation
Leidos is an applied solutions company focused on markets that are seeing converging business and technological trends, and address basic, enduring human needs: defense and national security, health and life sciences, and energy, engineering and infrastructure. The Company's approximately 20,000 employees serve customers in the U.S. Department of Defense, the intelligence community, the U.S. Department of Homeland Security, other U.S. Government civil agencies and commercial health and engineering markets. Leidos is an Equal Opportunity Employer M/F/D/V.